RxDoctor Payments Data

Harjyot Sohal, MD

Critical Care Medicine · Osage Beach, MONPI 1962468520

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,346 of the $10,243 with a category attached, or 62.0%. 37 manufacturers reported payments, led by Pulmonx Corporation at 40.8% of the total. Reporting peaked in 2024 at $3,563 and has fallen 74.2% since, to $919 in 2025. Among critical care medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,243in general payments, 2019–2025

Across 373 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$4K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • GSK$784
  • Regeneron Healthcare Solutions, Inc.$530
  • Sanofi$347
  • plus $2K from 31 others

What the payments were for

  • Consulting fees$2,71326%
  • Travel & lodging$1,16211%
  • Food & beverage$6,34662%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,243 in reported general payments places this provider in the 95th percentile of 208 critical care medicine providers in Missouri.

See all critical care medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$138,113
Medicare patients
542
Services billed
2,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate78$1,031,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter448$382,197
Breztri AerosphereBudesonide/Glycopyr/Formoterol358$305,497
NucalaMepolizumab69$259,872
Spiriva RespimatTiotropium Bromide217$152,162
Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-5012$132,427
Pirfenidone22$126,949
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5022$93,062
Breo ElliptaFluticasone/Vilanterol161$85,960
SymbicortBudesonide/Formoterol Fumarate275$80,275
Stiolto RespimatTiotropium Br/Olodaterol Hcl106$74,311
Dupixent PenDupilumab14$54,306
Incruse ElliptaUmeclidinium Bromide100$41,267
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$28,673
Advair HfaFluticasone Propion/Salmeterol44$22,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$1,075$1,270,893420 claims
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$784$821,377916 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,112$396,835657 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$203$93,06222 claims
PfizerEliquis$38$11,11317 claims
MerckDulera$56$7,88519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 208 critical care medicine providers in Missouri.

Other critical care medicine in Osage Beach

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →